Sarcomatoid
FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology
Molecular Medicine 2024 May 31 [Link] James Mei-Lin Chan, Yuan-Ching Chang, Hua-Chen Chan, Hsiu-Chuan Chan, Wei-Chin Chang, Liu-Fang Wang, Tung-Hu Tsai, Yu-Jen Chen, Wen-Chien Huang Abstract Human malignant pleural mesothelioma (hMPM) is an aggressive, rare disease with a poor prognosis. Histologically, MPM is categorized into epithelioid, biphasic, and sarcomatoid subtypes, with the epithelioid subtype generally…
Read MoreSarcomatoid malignant pleural mesothelioma: a case of long-term recurrence-free survival following curative intent surgery alone
Surgical Case Reports 2024 May 31 [Link] Masatoshi Kanayama, Masaru Takenaka, Katsuma Yoshimatsu, Hiroki Matsumiya, Masataka Mori, Koji Kuroda3, Aya Nawata, Manabu Yasuda, Fumihiro Tanaka Abstract Background: Curative intent surgery may be indicated for some patients with resectable early stage malignant pleural mesothelioma (MPM). However, sarcomatoid MPM is a highly aggressive subtype for which curative…
Read MoreDifferential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…
Read MoreDiagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis
Pathology, Research, and Practice 2024 March 30 [Link] Rafael Parra-Medina, Juan Pablo Castañeda-González, Viviana Chaves-Cabezas, Juan Pablo Alzate, Juan José Chaves Abstract Background: Malignant pleural mesothelioma (MPM) poses diagnostic challenges due to its resemblance to benign pleural pathologies and different histological subtypes. Several immunohistochemistry markers have been employed to aid in accurate diagnosis. Methods: The…
Read MoreDetailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues
BMJ Case Reports 2024 February 10 [Link] Keiichi Mizuhashi, Kenzo Okamoto, Kazuki Nabeshima, Takumi Kishimoto Abstract Sarcomatoid mesothelioma is difficult to differentiate from other mesotheliomas. Here, we describe the case of a man in his early 80s with sarcomatoid mesothelioma and a history of asbestos exposure. He initially presented with right-sided chest pain and was…
Read MoreBrief Report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma – RIOMeso
Journal of Thoracic Oncology 2023 November 15 [Link] N McNamee, C Harvey, L Gray, T Khoo, L Lingam, B Zhang, U Nindra, P Y Yip, A Pal, T Clay, S Arulananda, M Itchins, N Pavlakis, S Kao, S Bowyer, V Chin, L Warburton, I Pires da Silva, T John, B Solomon, M Alexander, A Nagrial…
Read MoreTreatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma
eLife 2023 November 13 [Link] Akshat Sarkari, Sophie Korenfeld, Karina Deniz, Katherine Ladner, Phillip Wong, Sanyukta Padmanabhan, Rachel I Vogel, Laura A Sherer, Naomi Courtemanche, Clifford Steer, Kerem Wainer-Katsir, Emil Lou Abstract Disruption of intercellular communication within tumors is emerging as a novel potential strategy for cancer-directed therapy. Tumor-Treating Fields (TTFields) therapy is a treatment…
Read MoreContribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology
European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…
Read MorePerioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read More